The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection

NCT04769245 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-02-24

No results posted yet for this study

Summary

Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.

Conditions

  • Covid19

Sponsors & Collaborators

  • Acıbadem Labcell

    collaborator OTHER
  • Acibadem University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-18
Primary Completion
2021-04-01
Completion
2021-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04769245 on ClinicalTrials.gov